Key details on Neurocrine Biosciences (Ticker: NBIX)
- CUSIP: 64125C109
- Is NBIX overvalued or undervalued? Run a discounted cash flow (DCF) valuation analysis on NBIX
Who owns Neurocrine Biosciences?
Is NBIX a good stock to own? Find out who bought Neurocrine Biosciences, who sold Neurocrine Biosciences (NBIX) stock, and who holds a large position in Neurocrine Biosciences.
|Fund Name||Number of Shares||Share Valuation||As Of|
|FMR||11.39M||$178.45M||Sept. 30, 2014|
|T. Rowe Price Associates||10.07M||$224.95M||Dec. 31, 2014|
|OrbiMed Advisors||5.97M||$133.34M||Dec. 31, 2014|
|BVF||5.93M||$50.40M||Dec. 31, 2011|
|Perceptive Advisors||5.17M||$115.39M||Dec. 31, 2014|
|BB Biotech AG||3.09M||$68.95M||Dec. 31, 2014|
|BlackRock Fund Advisors||2.85M||$63.65M||Dec. 31, 2014|
|Visium Asset Management||2.46M||$55.00M||Dec. 31, 2014|
|Vanguard||2.36M||$52.76M||Dec. 31, 2014|
|STATE STREET CORPORATION||2.09M||$46.64M||Dec. 31, 2014|
|BlackRock Institutional Trust Company, N.A.||2.04M||$45.54M||Dec. 31, 2014|
|VHCP Management||1.96M||$26.29M||June 30, 2013|
|Franklin Resources||1.93M||$43.03M||Dec. 31, 2014|
|S.A.C. Capital Advisors||1.88M||$14.07M||Dec. 31, 2012|
|Jennison Associates||1.64M||$18.59M||Sept. 30, 2013|
Who sold Neurocrine Biosciences?
|Fund Name||Date Sold||Number of Shares Sold||Share Valuation|
|Wellington Management Company||June 30, 2011||1.93M||$15.56M|